Found vs Brello: Biology-first care vs clinician-reviewed options

Found vs Brello is a side-by-side look at two telehealth approaches to weight-management care. Early verdict: Found emphasizes a biology-first, personalized medically supervised program with plans starting at $39 and insurance handling; Brello offers clinician-reviewed treatment but captured pricing, eligibility, pharmacy and state details were not verified.

Explore Found plans starting at $39

How these services differ at a glance

Both operate in online weight-management, but Found presents a detailed biology-focused model with specific pricing claims and insurance support. Brello’s captured landing-page evidence did not verify current pricing, features, or eligibility; its offering is described as clinician-reviewed and subject to live offer terms.

Distinctive differences covered in this comparison

• Approach and personalization
• Pricing transparency and insurance handling
• Medication types and regulatory notes
• State, eligibility and verification of details

Approach and personalization: Found vs Brello

Found positions itself as biology-first, building personalized medically supervised programs that target hormones, metabolism, sleep and behavioral factors. The source states Found does not prescribe a single medication protocol for all patients. For Brello, the captured evidence only notes that treatment is available when a licensed clinician determines it is medically appropriate; no further program details were verified.

Pricing transparency and insurance handling

Found: captured evidence repeatedly indicates pricing signals and insurance support. Found advertises plans starting at $39 or getting started for as low as $39, mentions membership pricing (starting at $49/mo when billed annually in some captures), and states “Most insurance now accepted” and “We handle insurance paperwork.” Several specific price claims appear on the landing evidence, such as “Get Wegovy®, Foundayo®, or Zepbound® for as little as $50/mo through Medicare,” with qualifiers about eligibility and program specifics. The source also includes promotional offer details and notes that advertised pricing for branded GLP-1s and non-GLP-1s may involve 12 month commitments and that copays, coinsurance and deductibles may apply.

Brello: the captured affiliate landing page failed to provide verified pricing or details. The source row explicitly states current details were not published or could not be verified on the captured affiliate landing page, and that pricing, eligibility, pharmacy, state coverage and renewal terms may change.

See Found insurance and pricing details

Medications, compounded products, and regulatory notes

Found: the captured evidence lists semaglutide and tirzepatide mentions, including “Compounded” next to Semaglutide and Tirzepatide in multiple places. The source includes an explicit regulatory note that “Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.” Found also states that certain medications are FDA-approved for conditions other than weight and includes disclaimers about affiliation with manufacturers. Rx is subject to provider review and clinical eligibility.

Brello: the landing capture notes that when compounded medications are offered, they are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The source also warns that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Beyond these regulatory cautions, no medication lists or pricing were captured.

State availability, eligibility, and verification

Found: captured evidence includes multiple qualifiers—compounded GLP-1s are “not available in all states,” Rx is “subject to provider review and clinical eligibility,” and insurance coverage, pricing and terms vary. Found claims it accepts insurance for about one third of Americans for compounded GLP-1s in the captured material, presented with qualifiers about eligibility and program specifics.

Brello: the captured row repeatedly notes that current details were not verified, advising people to confirm eligibility, medication, total cost, renewal terms and state availability before enrollment. The only verified structural statement is that treatment is available only when a licensed clinician determines it is medically appropriate.

Comparison table: Found vs Brello

End-of-article summary and pick guidance

Found vs Brello differs mainly in transparency and captured detail. Found’s captured evidence supplies specific pricing claims, insurance handling statements and a biology-first personalization pitch, with multiple regulatory qualifiers about compounded medications and eligibility. Brello’s captured evidence is limited: it emphasizes clinician review, and the capture did not verify pricing, eligibility, pharmacy, state coverage or renewal terms.

Start Found enrollment and insurance check

Choose Found if you want a biology-first, personalized medically supervised program with captured claims of plans starting at $39 and explicit insurance handling statements. Choose Brello if you prioritize clinician-reviewed treatment and will confirm live pricing, eligibility, pharmacy and state availability before enrolling.